Jeffrey Dierks serves as the Executive Vice President and Chief Commercial Officer at Harmony Biosciences Holdings Inc., a position he has held since joining the company. In his role, Dierks is responsible for overseeing the commercial strategy and operations of the company, driving growth and market expansion for Harmony's innovative treatments for rare neurological diseases. His leadership has been instrumental in guiding the company through the successful launch and ongoing commercialization of their flagship product, WAKIX® (pitolisant), which is approved for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Prior to joining Harmony Biosciences, Dierks held several senior leadership positions in the pharmaceutical industry, amassing over two decades of experience in commercial strategy, sales, and marketing. He previously served as Vice President of Sales at Teva Pharmaceuticals, where he played a key role in the successful launch and growth of several key products. Before Teva, Dierks held positions at Boehringer Ingelheim and Forest Laboratories, where he demonstrated a proven track record of driving revenue growth and market share expansion through innovative commercial strategies and effective team leadership. Dierks holds a Bachelor of Science degree in Business Administration from the University of Delaware. Throughout his career, he has been recognized for his strategic vision, operational excellence, and commitment to patient-centric healthcare solutions. At Harmony Biosciences, Dierks continues to lead the commercial team with a focus on expanding access to life-changing treatments for patients with rare neurological disorders, while also driving the company's mission to improve the lives of patients and their families.